Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 277

1.

Strategies in anti-Mycobacterium tuberculosis drug discovery based on phenotypic screening.

Grzelak EM, Choules MP, Gao W, Cai G, Wan B, Wang Y, McAlpine JB, Cheng J, Jin Y, Lee H, Suh JW, Pauli GF, Franzblau SG, Jaki BU, Cho S.

J Antibiot (Tokyo). 2019 Jul 11. doi: 10.1038/s41429-019-0205-9. [Epub ahead of print] Review.

PMID:
31292530
2.

Mce3R Stress-Resistance Pathway Is Vulnerable to Small-Molecule Targeting That Improves Tuberculosis Drug Activities.

Yang X, Yuan T, Ma R, Chacko KI, Smith M, Deikus G, Sebra R, Kasarskis A, van Bakel H, Franzblau SG, Sampson NS.

ACS Infect Dis. 2019 Jul 12;5(7):1239-1251. doi: 10.1021/acsinfecdis.9b00099. Epub 2019 May 3.

3.

Identification of Pyrazolo[1,5-a]pyridine-3-carboxamide Diaryl Derivatives as Drug Resistant Antituberculosis Agents.

Hu X, Wan B, Liu Y, Shen J, Franzblau SG, Zhang T, Ding K, Lu X.

ACS Med Chem Lett. 2019 Feb 21;10(3):295-299. doi: 10.1021/acsmedchemlett.8b00410. eCollection 2019 Mar 14.

PMID:
30891129
4.

3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel.

Sutherland HS, Tong AST, Choi PJ, Blaser A, Conole D, Franzblau SG, Lotlikar MU, Cooper CB, Upton AM, Denny WA, Palmer BD.

Bioorg Med Chem. 2019 Apr 1;27(7):1292-1307. doi: 10.1016/j.bmc.2019.02.026. Epub 2019 Feb 15.

5.

Quality Control of Therapeutic Peptides by 1H NMR HiFSA Sequencing.

Choules MP, Bisson J, Gao W, Lankin DC, McAlpine JB, Niemitz M, Jaki BU, Franzblau SG, Pauli GF.

J Org Chem. 2019 Mar 15;84(6):3055-3073. doi: 10.1021/acs.joc.8b02704. Epub 2019 Feb 22.

PMID:
30793905
6.

Structure-activity relationships for unit C pyridyl analogues of the tuberculosis drug bedaquiline.

Blaser A, Sutherland HS, Tong AST, Choi PJ, Conole D, Franzblau SG, Cooper CB, Upton AM, Lotlikar M, Denny WA, Palmer BD.

Bioorg Med Chem. 2019 Apr 1;27(7):1283-1291. doi: 10.1016/j.bmc.2019.02.025. Epub 2019 Feb 15.

7.

An iboga alkaloid chemotaxonomic marker from endemic Tabernaemontana ternifolia with antitubercular activity.

Garcellano RC, Cort JR, Moinuddin SGA, Franzblau SG, Ma R, Aguinaldo AM.

Nat Prod Res. 2019 Feb 17:1-5. doi: 10.1080/14786419.2018.1550759. [Epub ahead of print]

PMID:
30773907
8.

Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus.

Choules MP, Wolf NM, Lee H, Anderson JR, Grzelak EM, Wang Y, Ma R, Gao W, McAlpine JB, Jin YY, Cheng J, Lee H, Suh JW, Duc NM, Paik S, Choe JH, Jo EK, Chang CL, Lee JS, Jaki BU, Pauli GF, Franzblau SG, Cho S.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02204-18. doi: 10.1128/AAC.02204-18. Print 2019 Mar.

9.

Isolation of Tryptanthrin and Reassessment of Evidence for Its Isobaric Isostere Wrightiadione in Plants of the Wrightia Genus.

Garcellano RC, Moinuddin SGA, Young RP, Zhou M, Bowden ME, Renslow RS, Yesiltepe Y, Thomas DG, Colby SM, Chouinard CD, Nagy G, Attah IK, Ibrahim YM, Ma R, Franzblau SG, Lewis NG, Aguinaldo AM, Cort JR.

J Nat Prod. 2019 Mar 22;82(3):440-448. doi: 10.1021/acs.jnatprod.8b00567. Epub 2018 Oct 8.

PMID:
30295480
10.

An antimycobacterial pleuromutilin analogue effective against dormant bacilli.

Lemieux MR, Siricilla S, Mitachi K, Eslamimehr S, Wang Y, Yang D, Pressly JD, Kong Y, Park F, Franzblau SG, Kurosu M.

Bioorg Med Chem. 2018 Sep 15;26(17):4787-4796. doi: 10.1016/j.bmc.2018.07.034. Epub 2018 Aug 18.

11.

Synthesis and Activity against Mycobacterium tuberculosis of Olivacine and Oxygenated Derivatives.

Schmidt U, Theumer G, Jäger A, Kataeva O, Wan B, Franzblau SG, Knölker HJ.

Molecules. 2018 Jun 9;23(6). pii: E1402. doi: 10.3390/molecules23061402.

12.

Residual Complexity Does Impact Organic Chemistry and Drug Discovery: The Case of Rufomyazine and Rufomycin.

Choules MP, Klein LL, Lankin DC, McAlpine JB, Cho SH, Cheng J, Lee H, Suh JW, Jaki BU, Franzblau SG, Pauli GF.

J Org Chem. 2018 Jun 15;83(12):6664-6672. doi: 10.1021/acs.joc.8b00988. Epub 2018 May 24.

13.

Pyrazole and imidazo[1,2-b]pyrazole Derivatives as New Potential Antituberculosis Agents.

Meta E, Brullo C, Tonelli M, Franzblau SG, Wang Y, Ma R, Baojie W, Orena BS, Pasca MR, Bruno O.

Med Chem. 2019;15(1):17-27. doi: 10.2174/1573406414666180524084023.

PMID:
29792151
14.

Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles.

Sutherland HS, Tong AST, Choi PJ, Conole D, Blaser A, Franzblau SG, Cooper CB, Upton AM, Lotlikar MU, Denny WA, Palmer BD.

Bioorg Med Chem. 2018 May 1;26(8):1797-1809. doi: 10.1016/j.bmc.2018.02.026. Epub 2018 Feb 20.

15.

Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.

Thompson AM, O'Connor PD, Marshall AJ, Blaser A, Yardley V, Maes L, Gupta S, Launay D, Braillard S, Chatelain E, Wan B, Franzblau SG, Ma Z, Cooper CB, Denny WA.

J Med Chem. 2018 Mar 22;61(6):2329-2352. doi: 10.1021/acs.jmedchem.7b01581. Epub 2018 Mar 6.

16.

Small Molecules Targeting Mycobacterium tuberculosis Type II NADH Dehydrogenase Exhibit Antimycobacterial Activity.

Harbut MB, Yang B, Liu R, Yano T, Vilchèze C, Cheng B, Lockner J, Guo H, Yu C, Franzblau SG, Petrassi HM, Jacobs WR Jr, Rubin H, Chatterjee AK, Wang F.

Angew Chem Int Ed Engl. 2018 Mar 19;57(13):3478-3482. doi: 10.1002/anie.201800260. Epub 2018 Feb 22.

17.

Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid.

Thompson AM, Bonnet M, Lee HH, Franzblau SG, Wan B, Wong GS, Cooper CB, Denny WA.

ACS Med Chem Lett. 2017 Nov 13;8(12):1275-1280. doi: 10.1021/acsmedchemlett.7b00356. eCollection 2017 Dec 14.

18.

Antitubercular and Cytotoxic Chlorinated seco-Cyclohexenes from Uvaria alba.

Macabeo APG, Letada AG, Budde S, Faderl C, Dahse HM, Franzblau SG, Alejandro GJD, Pierens GK, Garson MJ.

J Nat Prod. 2017 Dec 22;80(12):3319-3323. doi: 10.1021/acs.jnatprod.7b00679. Epub 2017 Nov 27.

PMID:
29172496
19.

Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units.

Choi PJ, Sutherland HS, Tong AST, Blaser A, Franzblau SG, Cooper CB, Lotlikar MU, Upton AM, Guillemont J, Motte M, Queguiner L, Andries K, Van den Broeck W, Denny WA, Palmer BD.

Bioorg Med Chem Lett. 2017 Dec 1;27(23):5190-5196. doi: 10.1016/j.bmcl.2017.10.042. Epub 2017 Oct 20.

20.

6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis.

Tong AST, Choi PJ, Blaser A, Sutherland HS, Tsang SKY, Guillemont J, Motte M, Cooper CB, Andries K, Van den Broeck W, Franzblau SG, Upton AM, Denny WA, Palmer BD, Conole D.

ACS Med Chem Lett. 2017 Sep 22;8(10):1019-1024. doi: 10.1021/acsmedchemlett.7b00196. eCollection 2017 Oct 12.

21.

Structural Sequencing of Oligopeptides Aided by 1H Iterative Full-Spin Analysis.

Gao W, McAlpine JB, Choules MP, Napolitano JG, Lankin DC, Simmler C, Ho NA, Lee H, Suh JW, Burton IW, Cho S, Franzblau SG, Chen SN, Pauli GF.

J Nat Prod. 2017 Oct 27;80(10):2630-2643. doi: 10.1021/acs.jnatprod.7b00207. Epub 2017 Oct 16.

PMID:
29035048
22.

Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity.

Dos Santos Fernandes GF, de Souza PC, Moreno-Viguri E, Santivañez-Veliz M, Paucar R, Pérez-Silanes S, Chegaev K, Guglielmo S, Lazzarato L, Fruttero R, Man Chin C, da Silva PB, Chorilli M, Solcia MC, Ribeiro CM, Silva CSP, Marino LB, Bosquesi PL, Hunt DM, de Carvalho LPS, de Souza Costa CA, Cho SH, Wang Y, Franzblau SG, Pavan FR, Dos Santos JL.

J Med Chem. 2017 Oct 26;60(20):8647-8660. doi: 10.1021/acs.jmedchem.7b01332. Epub 2017 Oct 16.

23.

In Vitro Activities of Enantiopure and Racemic 1'-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis.

Warit S, Rukseree K, Prammananan T, Hongmanee P, Billamas P, Jaitrong S, Chaiprasert A, Jaki BU, Pauli GF, Franzblau SG, Palittapongarnpim P.

Sci Pharm. 2017 Sep 18;85(3). pii: E32. doi: 10.3390/scipharm85030032.

24.

Biophysical Screening of a Focused Library for the Discovery of CYP121 Inhibitors as Novel Antimycobacterials.

Brengel C, Thomann A, Schifrin A, Allegretta G, Kamal AAM, Haupenthal J, Schnorr I, Cho SH, Franzblau SG, Empting M, Eberhard J, Hartmann RW.

ChemMedChem. 2017 Oct 9;12(19):1616-1626. doi: 10.1002/cmdc.201700363. Epub 2017 Sep 26.

PMID:
28815923
25.

Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes.

Liu R, Lyu X, Batt SM, Hsu MH, Harbut MB, Vilchèze C, Cheng B, Ajayi K, Yang B, Yang Y, Guo H, Lin C, Gan F, Wang C, Franzblau SG, Jacobs WR Jr, Besra GS, Johnson EF, Petrassi M, Chatterjee AK, Fütterer K, Wang F.

Angew Chem Int Ed Engl. 2017 Oct 9;56(42):13011-13015. doi: 10.1002/anie.201707324. Epub 2017 Sep 7.

26.

Discovery of new leads against Mycobacterium tuberculosis using scaffold hopping and shape based similarity.

Wavhale RD, Martis EAF, Ambre PK, Wan B, Franzblau SG, Iyer KR, Raikuvar K, Macegoniuk K, Berlicki Ł, Nandan SR, Coutinho EC.

Bioorg Med Chem. 2017 Sep 1;25(17):4835-4844. doi: 10.1016/j.bmc.2017.07.034. Epub 2017 Jul 19.

PMID:
28778369
27.

Exploring the Sponge Consortium Plakortis symbiotica-Xestospongia deweerdtae as a Potential Source of Antimicrobial Compounds and Probing the Pharmacophore for Antituberculosis Activity of Smenothiazole A by Diverted Total Synthesis.

Jiménez-Romero C, Rode JE, Pérez YM, Franzblau SG, Rodríguez AD.

J Nat Prod. 2017 Aug 25;80(8):2295-2303. doi: 10.1021/acs.jnatprod.7b00300. Epub 2017 Jul 25.

PMID:
28742349
28.

QSAR-driven design, synthesis and discovery of potent chalcone derivatives with antitubercular activity.

Gomes MN, Braga RC, Grzelak EM, Neves BJ, Muratov E, Ma R, Klein LL, Cho S, Oliveira GR, Franzblau SG, Andrade CH.

Eur J Med Chem. 2017 Sep 8;137:126-138. doi: 10.1016/j.ejmech.2017.05.026. Epub 2017 May 10.

29.

Sweet spot matching: A thin-layer chromatography-based countercurrent solvent system selection strategy.

Liu Y, Friesen JB, Grzelak EM, Fan Q, Tang T, Durić K, Jaki BU, McAlpine JB, Franzblau SG, Chen SN, Pauli GF.

J Chromatogr A. 2017 Jun 30;1504:46-54. doi: 10.1016/j.chroma.2017.04.055. Epub 2017 Apr 27.

30.

6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases.

Thompson AM, Blaser A, Palmer BD, Anderson RF, Shinde SS, Launay D, Chatelain E, Maes L, Franzblau SG, Wan B, Wang Y, Ma Z, Denny WA.

Bioorg Med Chem Lett. 2017 Jun 1;27(11):2583-2589. doi: 10.1016/j.bmcl.2017.03.069. Epub 2017 Mar 27.

PMID:
28462832
31.

7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.

Thompson AM, O'Connor PD, Marshall AJ, Yardley V, Maes L, Gupta S, Launay D, Braillard S, Chatelain E, Franzblau SG, Wan B, Wang Y, Ma Z, Cooper CB, Denny WA.

J Med Chem. 2017 May 25;60(10):4212-4233. doi: 10.1021/acs.jmedchem.7b00034. Epub 2017 May 11.

32.

Benzylsulfanyl benzo-heterocycle amides and hydrazones as new agents against drug-susceptible and resistant Mycobacterium tuberculosis.

Lu X, Hu X, Liu Z, Zhang T, Wang R, Wan B, Franzblau SG, You Q.

Medchemcomm. 2017 Apr 28;8(6):1303-1306. doi: 10.1039/c7md00146k. eCollection 2017 Jun 1.

33.

Computer-aided discovery of two novel chalcone-like compounds active and selective against Leishmania infantum.

Gomes MN, Alcântara LM, Neves BJ, Melo-Filho CC, Freitas-Junior LH, Moraes CB, Ma R, Franzblau SG, Muratov E, Andrade CH.

Bioorg Med Chem Lett. 2017 Jun 1;27(11):2459-2464. doi: 10.1016/j.bmcl.2017.04.010. Epub 2017 Apr 4.

34.

Anti-tuberculosis activity and structure-activity relationships of oxygenated tricyclic carbazole alkaloids and synthetic derivatives.

Börger C, Brütting C, Julich-Gruner KK, Hesse R, Kumar VP, Kutz SK, Rönnefahrt M, Thomas C, Wan B, Franzblau SG, Knölker HJ.

Bioorg Med Chem. 2017 Nov 15;25(22):6167-6174. doi: 10.1016/j.bmc.2016.12.038. Epub 2016 Dec 27.

PMID:
28094223
35.

Attenuation of Mycobacterium species through direct and macrophage mediated pathway by unsymmetrical diaryl urea.

Velappan AB, Charan Raja MR, Datta D, Tsai YT, Halloum I, Wan B, Kremer L, Gramajo H, Franzblau SG, Kar Mahapatra S, Debnath J.

Eur J Med Chem. 2017 Jan 5;125:825-841. doi: 10.1016/j.ejmech.2016.09.083. Epub 2016 Sep 26.

PMID:
27750200
36.

Arrival of Imidazo[2,1-b]thiazole-5-carboxamides: Potent Anti-tuberculosis Agents That Target QcrB.

Moraski GC, Seeger N, Miller PA, Oliver AG, Boshoff HI, Cho S, Mulugeta S, Anderson JR, Franzblau SG, Miller MJ.

ACS Infect Dis. 2016 Jun 10;2(6):393-8. doi: 10.1021/acsinfecdis.5b00154. Epub 2016 Apr 12.

PMID:
27627627
37.

Fluorescence-based assay for polyprenyl phosphate-GlcNAc-1-phosphate transferase (WecA) and identification of novel antimycobacterial WecA inhibitors.

Mitachi K, Siricilla S, Yang D, Kong Y, Skorupinska-Tudek K, Swiezewska E, Franzblau SG, Kurosu M.

Anal Biochem. 2016 Nov 1;512:78-90. doi: 10.1016/j.ab.2016.08.008. Epub 2016 Aug 13.

38.

Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase.

Palencia A, Li X, Bu W, Choi W, Ding CZ, Easom EE, Feng L, Hernandez V, Houston P, Liu L, Meewan M, Mohan M, Rock FL, Sexton H, Zhang S, Zhou Y, Wan B, Wang Y, Franzblau SG, Woolhiser L, Gruppo V, Lenaerts AJ, O'Malley T, Parish T, Cooper CB, Waters MG, Ma Z, Ioerger TR, Sacchettini JC, Rullas J, Angulo-Barturen I, Pérez-Herrán E, Mendoza A, Barros D, Cusack S, Plattner JJ, Alley MR.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6271-80. doi: 10.1128/AAC.01339-16. Print 2016 Oct.

39.

Bioautography with TLC-MS/NMR for Rapid Discovery of Anti-tuberculosis Lead Compounds from Natural Sources.

Grzelak EM, Hwang C, Cai G, Nam JW, Choules MP, Gao W, Lankin DC, McAlpine JB, Mulugeta SG, Napolitano JG, Suh JW, Yang SH, Cheng J, Lee H, Kim JY, Cho SH, Pauli GF, Franzblau SG, Jaki BU.

ACS Infect Dis. 2016 Apr 8;2(4):294-301. Epub 2016 Feb 23.

40.

Antimycobacterial activity of pyrazinoate prodrugs in replicating and non-replicating Mycobacterium tuberculosis.

Segretti ND, Simões CK, Corrêa MF, Felli VM, Miyata M, Cho SH, Franzblau SG, Fernandes JP.

Tuberculosis (Edinb). 2016 Jul;99:11-6. doi: 10.1016/j.tube.2016.04.002. Epub 2016 Apr 9.

PMID:
27449999
41.

Imidazo[1,2-a]Pyridine-3-Carboxamides Are Active Antimicrobial Agents against Mycobacterium avium Infection In Vivo.

Moraski GC, Cheng Y, Cho S, Cramer JW, Godfrey A, Masquelin T, Franzblau SG, Miller MJ, Schorey J.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):5018-22. doi: 10.1128/AAC.00618-16. Print 2016 Aug.

42.

Bioassay-Guided Isolation and Structural Modification of the Anti-TB Resorcinols from Ardisia gigantifolia.

Guan YF, Song X, Qiu MH, Luo SH, Wang BJ, Van Hung N, Cuong NM, Soejarto DD, Fong HH, Franzblau SG, Li SH, He ZD, Zhang HJ.

Chem Biol Drug Des. 2016 Aug;88(2):293-301. doi: 10.1111/cbdd.12756. Epub 2016 Apr 26.

PMID:
26992112
43.

Design, Syntheses, and Anti-TB Activity of 1,3-Benzothiazinone Azide and Click Chemistry Products Inspired by BTZ043.

Tiwari R, Miller PA, Chiarelli LR, Mori G, Šarkan M, Centárová I, Cho S, Mikušová K, Franzblau SG, Oliver AG, Miller MJ.

ACS Med Chem Lett. 2016 Jan 4;7(3):266-70. doi: 10.1021/acsmedchemlett.5b00424. eCollection 2016 Mar 10.

44.

Design, syntheses, and anti-tuberculosis activities of conjugates of piperazino-1,3-benzothiazin-4-ones (pBTZs) with 2,7-dimethylimidazo [1,2-a]pyridine-3-carboxylic acids and 7-phenylacetyl cephalosporins.

Majewski MW, Tiwari R, Miller PA, Cho S, Franzblau SG, Miller MJ.

Bioorg Med Chem Lett. 2016 Apr 15;26(8):2068-71. doi: 10.1016/j.bmcl.2016.02.076. Epub 2016 Feb 27.

45.

Syntheses and Biological Evaluations of Highly Functionalized Hydroxamate Containing and N-Methylthio Monobactams as Anti-Tuberculosis and β-Lactamase Inhibitory Agents.

Majewski MW, Watson KD, Cho S, Miller PA, Franzblau SG, Miller MJ.

Medchemcomm. 2016 Jan 1;7(1):141-147. Epub 2015 Oct 5.

46.

Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.

Thompson AM, O'Connor PD, Blaser A, Yardley V, Maes L, Gupta S, Launay D, Martin D, Franzblau SG, Wan B, Wang Y, Ma Z, Denny WA.

J Med Chem. 2016 Mar 24;59(6):2530-50. doi: 10.1021/acs.jmedchem.5b01699. Epub 2016 Mar 8.

47.

Natural product-based synthesis of novel anti-infective isothiocyanate- and isoselenocyanate-functionalized amphilectane diterpenes.

Nieves K, Prudhomme J, Le Roch KG, Franzblau SG, Rodríguez AD.

Bioorg Med Chem Lett. 2016 Feb 1;26(3):854-857. doi: 10.1016/j.bmcl.2015.12.080. Epub 2015 Dec 22.

48.

Diaza-anthracene Antibiotics from a Freshwater-Derived Actinomycete with Selective Antibacterial Activity toward Mycobacterium tuberculosis.

Mullowney MW, Hwang CH, Newsome AG, Wei X, Tanouye U, Wan B, Carlson S, Barranis NJ, hAinmhire E, Chen WL, Krishnamoorthy K, White J, Blair R, Lee H, Burdette JE, Rathod PK, Parish T, Cho S, Franzblau SG, Murphy BT.

ACS Infect Dis. 2015 Apr 10;1(4):168-174. Epub 2015 Mar 11.

49.

Synthesis and preliminary biological evaluation of a small library of hybrid compounds based on Ugi isocyanide multicomponent reactions with a marine natural product scaffold.

Avilés E, Prudhomme J, Le Roch KG, Franzblau SG, Chandrasena K, Mayer AM, Rodríguez AD.

Bioorg Med Chem Lett. 2015 Nov 15;25(22):5339-43. doi: 10.1016/j.bmcl.2015.09.033. Epub 2015 Sep 15.

50.

glpx Gene in Mycobacterium tuberculosis Is Required for In Vitro Gluconeogenic Growth and In Vivo Survival.

Gutka HJ, Wang Y, Franzblau SG, Movahedzadeh F.

PLoS One. 2015 Sep 23;10(9):e0138436. doi: 10.1371/journal.pone.0138436. eCollection 2015.

Supplemental Content

Loading ...
Support Center